Swedish Orphan Biovitrum (BIOVF) Earnings Date, Estimates & Call Transcripts $30.75 +1.78 (+6.14%) As of 08/22/2025 10:26 AM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestBuy This Stock Swedish Orphan Biovitrum Earnings Summary Swedish Orphan Biovitrum announced Q2 2025 earnings on July 16, 2025, reporting an EPS of $0.24, which beat the consensus estimate of $0.18 by $0.06. Quarterly revenue was reported to be $649.61 million, above analysts' expectations of $644.68 million. Swedish Orphan Biovitrum currently has a trailing EPS of $1.19 and a P/E Ratio of 25.84Q2 2025 Earnings ResourcesQ2 2025 Earnings ReportBIOVF Upcoming EarningsSwedish Orphan Biovitrum's next earnings date is estimated for Thursday, October 23, 2025, based on past reporting schedules. Upcoming Q3 Earnings DateOct. 23Before Market OpensEstimatedConsensus EPS (Jul. 16) $0.18 Actual EPS (Jul. 16) $0.24 Beat By $0.06 Actual Revenue (Jul. 16) $649.61M Get Swedish Orphan Biovitrum Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Swedish Orphan Biovitrum and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataBIOVF Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BIOVF Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Swedish Orphan Biovitrum Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 10/23/2025(Estimated)--------7/16/2025Q2 2025$0.18$0.24+$0.06$0.19$644.68M$649.61M4/29/2025Q1 2025$0.2152$0.26+$0.0448$0.24$644.12M$641.33M7/16/2024Q2 2024-$0.07-$0.08-$509.05M4/25/2024Q1 2024-$0.26-$0.30-$601.91M2/8/2024Q4 2023$0.56$0.30 -$0.26$0.32$668.74M$643.39M10/30/2023Q3 2023$0.09$0.05 -$0.04$0.07$443.96M$478.11M More Earnings Resources from MarketBeat Related Companies argenex Earnings Insmed Earnings BioNTech Earnings Royalty Pharma Earnings Biogen Earnings Incyte Earnings Genmab A/S Earnings Illumina Earnings Genmab A/S Earnings Ascendis Pharma A/S Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity This page (OTCMKTS:BIOVF) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Swedish Orphan Biovitrum Please log in to your account or sign up in order to add this asset to your watchlist. Share Swedish Orphan Biovitrum With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access